423 related articles for article (PubMed ID: 1338626)
21. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation on the effect of supplementary immunization for poliomyelitis elimination in Hainan province].
Pan XH
Zhonghua Liu Xing Bing Xue Za Zhi; 1996 Jun; 17(3):131-3. PubMed ID: 9208505
[TBL] [Abstract][Full Text] [Related]
23. [A study on immunization of polio vaccine. I. Observation on an improved immunization schedule].
Su W
Zhonghua Liu Xing Bing Xue Za Zhi; 1991 Oct; 12(5):281-3. PubMed ID: 1664295
[TBL] [Abstract][Full Text] [Related]
24. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
[TBL] [Abstract][Full Text] [Related]
25. The maintaining of the active laboratory-based surveillance of the acute flaccid paralysis (AFP) cases in Romania in the framework of the strategic plan of the global polio eradication initiative.
Băicuş A; Persu A; Combiescu M; Aubert-Combiescu A
Roum Arch Microbiol Immunol; 2007; 66(1-2):44-50. PubMed ID: 18928063
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
[TBL] [Abstract][Full Text] [Related]
27. Poliovirus antibody in children from a paediatric hospital in Ibadan, Nigeria.
Williams JO; David-West TS
Rev Roum Virol; 1990; 41(2):129-32. PubMed ID: 2176534
[TBL] [Abstract][Full Text] [Related]
28. Neutralising antibody response to oral poliovirus vaccine after primary immunisation with inactivated poliovirus vaccine.
Guérin N; Bregère P; Caudrelier P; Raynaud O
Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):815-6. PubMed ID: 9923532
[No Abstract] [Full Text] [Related]
29. A survey for neutralizing antibodies to the three types of poliovirus among children in Maiduguri, Nigeria.
Baba MM; Haruna BA; Ogunmola O; Ambe JP; Shidali NN; Oderinde B; Marcello A; Talle M
J Med Virol; 2012 Apr; 84(4):691-6. PubMed ID: 22337311
[TBL] [Abstract][Full Text] [Related]
30. [Isolates of poliovirus vaccine and immune response to different doses of oral polio vaccine].
Más Lago P; Díaz J; Díaz Gonzalez M; Goyenechea Hernández A; Barrio Olivera J; Fonseca Quintana M; Morier Díaz L; Sarmiento Pérez L; Palomera Puente R
Rev Cubana Med Trop; 2005; 57(2):111-9. PubMed ID: 17966580
[TBL] [Abstract][Full Text] [Related]
31. [Levels of specific antibodies against poliomyelitis virus and degree of immune protection in Umbria population].
Stagni G; Merletti L; De Rosa F
Boll Ist Sieroter Milan; 1979 Jul; 58(3):210-5. PubMed ID: 229884
[TBL] [Abstract][Full Text] [Related]
32. [Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan].
Akoua-Koffi G; Thonnon J; Kouassi-Renaud M; Dosso M; Ehouman A
Bull Soc Pathol Exot; 1995; 88(3):117-20. PubMed ID: 8555765
[TBL] [Abstract][Full Text] [Related]
33. Poliovirus antibodies in age groups: an assessment of obligatory vaccination in Belgium.
Lamy ME; Cornu C; Desmyter J
Dev Biol Stand; 1979; 43():207-13. PubMed ID: 230111
[TBL] [Abstract][Full Text] [Related]
34. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: Implications for future polio vaccination strategies.
Pírez MC; Olivera I; Diabarboure H; Montano A; Barañano R; Badía F; Bonnet MC
Vaccine; 2009 May; 27(20):2689-94. PubMed ID: 19428880
[TBL] [Abstract][Full Text] [Related]
35. A cross-sectional sero epidemiological prevalence of polio virus antibodies post-immunization with three doses of TOPV.
Tswana SA; Berejena C; Moyo SR; Mudyarabikwa O
Cent Afr J Med; 1994 Nov; 40(11):303-5. PubMed ID: 7859270
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt.
Linkins RW; Mansour E; Wassif O; Hassan MH; Patriarca PA
Bull World Health Organ; 1995; 73(5):589-95. PubMed ID: 8846484
[TBL] [Abstract][Full Text] [Related]
37. Antibody to poliovirus in older children and young adults in Israel and the use of poliovaccines for the immunization of the seronegatives.
Goldblum N; Kra-Oz Z; Swartz T
Dev Biol Stand; 1979; 43():173-7. PubMed ID: 230108
[TBL] [Abstract][Full Text] [Related]
38. Monovalent type 1 oral poliovirus vaccine in newborns.
el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of oral poliomyelitis vaccine (OPV) against variants of wild poliovirus type 3.
Böthig B; Danes L; Dittmann S
Bull World Health Organ; 1990; 68(5):597-600. PubMed ID: 1963118
[TBL] [Abstract][Full Text] [Related]
40. Poliomyelitis: epidemiology and prophylaxis. 4. Serological and virological surveys conducted after a mass vaccination campaign for the control of a threatening poliomyelitis epidemic.
Metselaar D; McDonald K; Gemert W; Nottay B; Muli JM
Bull World Health Organ; 1977; 55(6):747-53. PubMed ID: 202417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
